This PharmaVoice article argues that patients should be viewed as partners in drug development. While big pharma companies are incorporating the patient experience more in R&D, it\u2019s not in a consistent manner. From informed consent forms and recruitment materials to study design, aspects of a trial can easily be adapted to include patient insights. Find out the mutual benefits to forming relationships with patients and how pharma companies are starting to applying this approach to their clinical trial studies. Contributing industry members include Signant Heath\u2019s Bill Byrom, AstraZeneca\u2019s Helena Chung, and Antidot\u2019s Lindsey Wahlstrom-Edwards.